BPIM
LGND icon

Brant Point Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Brant Point Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-32,060
Closed -$1.95M – 132
2015
Q2 		$2.02M Buy
+32,060
New +$1.75M 0.18% 114

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brant Point Investment Management's LGND Position: Q3 2015 in Review

Brant Point Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2015, closing a stake of 32,060 shares — an estimated $1.95M sold.

Brant Point Investment Management first reported a position in LGND in Q2 2015 and held it in 1 quarter. The position peaked at $2.02M in Q2 2015. 203 funds tracked by Wall St. Rank hold LGND as of Q3 2015.

  • Brant Point Investment Management reported no remaining Ligand Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Brant Point Investment Management sold 32,060 Ligand Pharmaceuticals shares in Q3 2015, an estimated $1.95M.
  • Brant Point Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Brant Point Investment Management's Ligand Pharmaceuticals position peaked at $2.02M in Q2 2015.
  • 203 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2015.

Based on Brant Point Investment Management's 13F filing for Q3 2015, filed 13 Nov 2015.